Cited 27 times in
Molecular Testing of Lung Cancers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 심효섭 | - |
dc.date.accessioned | 2018-07-20T07:51:03Z | - |
dc.date.available | 2018-07-20T07:51:03Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2383-7837 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160591 | - |
dc.description.abstract | Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories-mutations, gene rearrangements, and amplifications-and propose expanded guidelines on molecular testing of lung cancers. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | The Korean Society of Pathologists | - |
dc.relation.isPartOf | JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Molecular Testing of Lung Cancers | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pathology | - |
dc.contributor.googleauthor | Hyo Sup Shim | - |
dc.contributor.googleauthor | Yoon-La Choi | - |
dc.contributor.googleauthor | Lucia Kim | - |
dc.contributor.googleauthor | Sunhee Chang | - |
dc.contributor.googleauthor | Wan-Seop Kim | - |
dc.contributor.googleauthor | Mee Sook Roh | - |
dc.contributor.googleauthor | Tae-Jung Kim | - |
dc.contributor.googleauthor | Seung Yeon Ha | - |
dc.contributor.googleauthor | Jin-Haeng Chung | - |
dc.contributor.googleauthor | Se Jin Jang | - |
dc.contributor.googleauthor | Geon Kook Lee | - |
dc.contributor.googleauthor | The Korean Cardiopulmonary Pathology Study Group | - |
dc.contributor.googleauthor | and The Korean Molecular Pathology Study Group | - |
dc.identifier.doi | 10.4132/jptm.2017.04.10 | - |
dc.contributor.localId | A02219 | - |
dc.relation.journalcode | J01680 | - |
dc.identifier.eissn | 2383-7845 | - |
dc.identifier.pmid | 28427247 | - |
dc.subject.keyword | Guideline | - |
dc.subject.keyword | Lung neopla는 | - |
dc.subject.keyword | Molecular testing | - |
dc.subject.keyword | Precision medicine | - |
dc.contributor.alternativeName | Shim, Hyo Sup | - |
dc.contributor.affiliatedAuthor | Shim, Hyo Sup | - |
dc.citation.volume | 51 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 242 | - |
dc.citation.endPage | 254 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, Vol.51(3) : 242-254, 2017 | - |
dc.identifier.rimsid | 48989 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.